Targeting histone lysine demethylase KDM4A in Aggressive Variant Prostate Cancer
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ABSTRACT

Background: Despite advancement in treatment, prostate cancer
remains the second leading cause of death among men. Prostate
cancer patients treated with potent second-generation anti-androgen
inhibitors such as enzalutamide and abiraterone inevitably develop
therapeutic resistance and progress to castration-resistant prostate
cancer (CRPC). Neuroendocrine prostate cancer (NEPC), which has
a median survival of 7 months after initial diagnosis, represents one
of the most lethal forms of CRPC. In contrast, castration-resistant
prostate adenocarcinoma, the more common subtype of CRPC, has
a median survival of 13 to 31 months, depending on the organ sites
of metastasis. NEPC is characterized by attenuated androgen
receptor (AR) signaling, the expression of neuroendocrine lineage
markers (e.g., synaptophysin), uncontrolled hyperproliferation, and
widespread metastasis (e.g., bone, liver, and lung). De novo NEPCs
are rare (2%-5%); the majority arises as a mechanism of resistance
from prostate adenocarcinoma treated with potent AR pathway
inhibitors (ARPIs). The widespread use of ARPIs in non-metastatic
CRPC and hormone-sensitive metastatic tumors has led to an
increase in the incidence NEPC. Due to the lack of life-prolonging
systemic therapies, there is an urgent need to better understand the
mechanisms underlying the pathogenesis of NEPC.
Recent evidence suggests that epigenetic dysregulation is a
hallmark of NEPC. Among the various epigenetic regulatory
mechanisms, histone lysine methylation, which is balanced by
writers (histone lysine methyltransferase [KMT]) and erasers (histone
lysine demethylases [KDM]), plays an important role in development
and cancer, including prostate. However, whether KDMs play any
roles in NEPC progression is unknown.
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(D) No observable differences between cell types in whole white blood count and (E) major organs weight,
suggesting QC6352 has no concernable adverse effects of QC6352 on mice.

F

E

KDM4A regulates MYC expression in NEPC cells
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IHC results shows that KDM4A is overexpressed in (D) (Left) mouse NEPC but not in
Adenocarcinoma. Similar result is also observed in (D) (Right) patient-derived xenograft tissue
microarray. (E) KDM4A is highly expressed in tumor of 3 of the NEPC generated GEMM model
(PTR, PSTR and TRAMP) compared to the adenocarcinoma model (PS). (F) KDM4A has a strong
correlation with multiple neuroendocrine (NE) markers, including CHGA and CHGB. (G) Both mouse
cell lines derived from the NEPC models (Left) PTR and (Right) PSTR have upregulated NEPC
markers compared to Adeno cell line MYC-CAP.

KDM4A KD or KO impairs NEPC growth in vitro and in vivo
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Figure 3. KDM4 inhibitor QC6352 renders tumor growth and induces apoptosis in both
human and mouse NEPC cells in vitro
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(A) QC6352 treatment drastically increases the level of both KDM4A substrates, H3K9me3 and
H3K36me3. QC treatment drastically reduces proliferation of both (B) mouse PSTR and (C) human
144-13 NEPC cells in a dose dependent manner. (D) KO of KDM4A abrogates PSTR response to
QC6352. (E,G) QC6352 treatment increases c-Caspase3 and c-PARP expression in PSTR and 144-13
cells. (F) Significant increase in caspase3/7 signal in QC treated cells compared to control.

KDM4 inhibitor hinders NEPC progression in vivo
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Figure 6. KDM4A regulates MYC pathways in NEPC

(A-B) GSEA on RNA-seq of Kdm4a-KD and –control PTR cells identifies MYC signatures as the top
downregulated pathways in Kdm4a KD cells. On the other hand, MYC pathways are the top hallmark
pathways activated in both human and mouse NEPC. (C) MYC target genes are significantly downregulated
in Kdm4a-KD cells. (D) MYC mRNA is downregulated in mouse squamous cell carcinoma cells with Kdm4a
KO compared to control cells and in QC6352 treated triple-negative breast cancer cells. Both protein and
mRNA expressions of MYC in Kdm4a KD (E) PSTR and (F) PTR cells are reduced significantly when
compared to control cells. (G) KD KDM4A in 144-13 cells drastically reduced MYC protein expression. (H)
CHIP-seq in 144-13 cells shows that KDM4A binds to MYC promotor, suggesting an active MYC
transcription in NEPC cells.

B

RESULTS

KDM4A is overexpressed in NEPC

CONCLUSIONS

A

G

H

I
C

D

Tumor
QC
Veh
KDM4A

Figure 2. Loss of function of KDM4A hinders growth of NEPC cells in vitro and
reduces tumor burden and delay NEPC appearance in vivo
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Figure 1. KDM4A is overexpressed in NEPC
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Figure 1. KDM4A is overexpressed in NEPC (Continued)

Figure 1. Structure of the KDM4 family proteins and schematic mechanism of enzymatic
activity of the family (Reference 1 & 2).
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Methods: By perturbation of KDM4A expression (overexpression,
knockdown and knockout) and inhibition of KDM4A functions with
small-molecule inhibitors in multiple model systems in vitro and in
vivo, we will determine the function of KDM4A and the potential
regulatory pathway of KDM4A in AVPC.
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Figure 4. (Continued). QC6352 suppressed NEPC progression in vivo
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KDM4 inhibitors suppressed NEPC growth and induce
apoptosis in vitro
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(A,B) KDM4A and KDM5D were uniquely upregulated in NEPC compared to Adeno-CRPC and SCPC
in genome-wide gene analysis. (C) KDM4A but not KDM5D is upregulated in (Blue bar) advanced tumors
of older mice compared to younger mice and (Red Bar) also in more aggressive tumor of PNR mice
compared to PN and PNRhet mice.

Knockdown of KDM4A reduced cell proliferation in both (A) mouse PSTR cells and (B) human 144-13
cells. (C-D) Silencing KDM4A in both mouse and human NEPC cells significantly reduces the number
of colonies and the sizes of the colonies formed by the cells in anchorage independence assay. (E)
KDM4A KO significantly reduces subQ tumor growth in vivo. (F) Conditional KO of KDM4A in PbCre;Kdm4af/f;TRAMP model leads to significant reduction of tumor burden compared to the NEPC
developing TRAMP model. (G) A longer overall survival is observed in conditional KO model whereas
(H) IHC for Ki67 shows a reduction of cell proliferation in KO tumors. (I) Kdm4a KO results in a
reduction of NEPC incident in older mice.

Our findings demonstrated that histone lysine demethylase KDM4A plays an
undeniable role in the progression of NEPC in prostate cancer through
regulating MYC and the downstream pathways. Targeting KDM4A can
potentially be an effective therapeutic option for combating NEPC. In the
future, we will further delineate and confirm the detailed mechanism of which
KDM4A regulates MYC, be it by directly binding to the MYC promotor or its
function as a transcriptional co-activator. We will also explore the therapeutic
potential to leverage the combination of silencing KDM4A by either RNAi or
QC6325 treatment with chemotherapy, with the aim to reduce side effects of
chemotherapy on patients.
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